Meet Monica Loghin, M.D.
Monica E. Loghin, M. D.
Department of Neuro-Oncology, Division of Cancer Medicine
About Dr. Loghin
Dr. Loghin is a professor in the Department of Neuro-Oncology who specializes in neurological complications related to cancer treatment, particularly neurological and cognitive defects induced by radiation therapy. She received her medical degree from Grigore T. Popa University of Medicine and Pharmacy, clinical residency at the University of Texas Health Science Center, and clinical fellowship at MD Anderson. She joined the MD Anderson faculty in 2006. Dr. Loghin is involved in patient clinical care as well as in the training program for Neuro-Oncology fellows and neurology residents. She currently serves as the Department of Neuro-Oncology Residency Program Director and also collaborates closely with the Neuro-psychology section in developing new therapeutic strategies for cancer-related cognitive dysfunction.
Present Title & Affiliation
Primary Appointment
Professor, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Research Interests
Dr. Loghin's research interests are focused on neurological complications related to cancer treatment, particularly neurological and cognitive deficits induced by radiation therapy. She is collaborating closely with the Neuropsychology Section in developing new therapeutic strategies for cancer related cognitive dysfunction.
Education & Training
Degree-Granting Education
1983 | "Gr.T. Popa" University of Medicine and Pharmacy, Iasi, ROM, MD, Medicine |
Postgraduate Training
2003-2005 | Clinical Fellowship, Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX |
2000-2003 | Clinical Residency, Neurology, UT Health Science Center, Houston, TX |
1999-2000 | Clinical Residency, Internal Medicine, UT Health Science Center, Houston, TX |
Board Certifications
2005 | The American Board of Psychiatry & Neurology |
1992 | The Romanian Board of Neurology |
Experience & Service
Academic Appointments
Associate Professor, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - 2021
Associate Professor, Department of Neurology, The University of Texas Medical Branch, Galveston, TX, 2010 - Present
Assistant Professor, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2006 - 2012
Administrative Appointments/Responsibilities
Residency Program Director, Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2007 - Present
Clerkship Program Director, Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2007 - Present
Honors & Awards
2011 | Nominated for Gerald P. Bodey Award for Excellence in Education, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center |
Selected Publications
Peer-Reviewed Articles
- Weathers SP, Han X, Liu DD, Conrad CA, Gilbert MR, Loghin ME, O'Brien BJ, Penas-Prado M, Puduvalli VK, Tremont-Lukats I, Colen RR, Yung WKA, de Groot JF. A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma. J Neurooncol 129(3):487-94, 2016. e-Pub 2016. PMID: 27406589.
- Kamiya-Matsuoka C, Paker AM, Chi L, Youssef A, Tummala S, Loghin ME. Posterior reversible encephalopathy syndrome in cancer patients: a single institution retrospective study. J Neurooncol 128(1):75-84, 2016. e-Pub 2016. PMID: 26900076.
- Raizer JJ, Giglio P, Hu J, Groves M, Merrell R, Conrad C, Phuphanich S, Puduvalli VK, Loghin M, Paleologos N, Yuan Y, Liu D, Rademaker A, Yung WK, Vaillant B, Rudnick J, Chamberlain M, Vick N, Grimm S, Tremont-Lukats IW, De Groot J, Aldape K, Gilbert MR, Brain Tumor Trials Collaborative. A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients. J Neurooncol 126(1):185-92, 2016. e-Pub 2015. PMID: 26476729.
- Rapp SR, Case LD, Peiffer A, Naughton MM, Chan MD, Stieber VW, Moore DF, Falchuk SC, Piephoff JV, Edenfield WJ, Giguere JK, Loghin ME, Shaw EG. Donepezil for Irradiated Brain Tumor Survivors: A Phase III Randomized Placebo-Controlled Clinical Trial. J Clin Oncol 33(15):1653-9, 2015. e-Pub 2015. PMID: 25897156.
- Penas-Prado M, Hess KR, Fisch MJ, Lagrone LW, Groves MD, Levin VA, De Groot JF, Puduvalli VK, Colman H, Volas-Redd G, Giglio P, Conrad CA, Salacz ME, Floyd JD, Loghin ME, Hsu SH, Gonzalez J, Chang EL, Woo SY, Mahajan A, Aldape KD, Yung WK, Gilbert MR, MD Anderson Community Clinical Oncology Program, Brain Tumor Trials Collaborative. Randomized Phase II Adjuvant Factorial Study of Dose-dense Temozolomide Alone and in Combination with Isotretinoin, Celecoxib, and/or Thalidomide for Glioblastoma. Neuro Oncol 17(2):266-73, 2015. e-Pub 2014. PMID: 25239666.
- Theeler BJ, Ellezam B, Yust-Katz S, Slopis JM, Loghin ME, de Groot JF. Prolonged survival in adult neurofibromatosis type I patients with recurrent high-grade gliomas treated with bevacizumab. J Neurol 261(8):1559-64, 2014. e-Pub 2014. PMID: 24859329.
- Abouharb S, Ensor J, Loghin ME, Katz R, Moulder SL, Esteva FJ, Smith B, Valero V, Hortobagyi GN, Melhem-Bertrandt A. Leptomeningeal disease and breast cancer: The importance of tumor subtype. Breast Cancer Res Treat 146(3):477-86, 2014. e-Pub 2014. PMID: 25038877.
- Le EM, Loghin ME. Posterior reversible encephalopathy syndrome: A neurologic phenomenon in cancer patients. Curr Oncol Rep 16(5):383-392, 2014. PMID: 24595679.
- Giglio P, Dhamne M, Hess KR, Gilbert MR, Groves MD, Levin VA, Kang SL, Ictech SE, Liu V, Colman H, Conrad CA, Loghin M, de Groot J, Yung WK, Puduvalli VK. Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma. Cancer 118(14):3599-606, 2012. e-Pub 2011. PMID: 22086614.
- Levin VA, Bidaut L, Hou P, Kumar AJ, Wefel JS, Bekele BN, Prabhu S, Loghin M, Gilbert MR, Jackson EF. Randomized Double-Blind Placebo-Controlled Trial of Bevacizumab Therapy for Radiation Necrosis of the Central Nervous System. Int J Radiat Oncol Biol Phys 79(5):1487-95, 2011. e-Pub 2010. PMID: 20399573.
- Loghin M, Prados M, Wen P, Junck L, Lieberman F, Fine H, Fink K, Mehta M, Kuhn J, Lamborn K, Chang S, Cloughesy T, DeAngelis L, Robins HI, Aldape K, Yung, WKA. Phase I study of Temozolomide and Irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: A North American Brain Tumor Consortium study. Clin Cancer Res 13(23):7133-7138, 2007. PMID: 18056194.
- Loghin M, Prodan R, Stefanache F. The role of evoked potentials in the diagnosis of posterior fossa tumors. Acta Neurologica Moldavica, 1994.
- Pendefunda G, Prodan R, Loghin M. Cerebral hemorrhage in blood disorders. Journal of the Society of Physicians and Nature Scientists, 1989.
Invited Articles
- Vaillant B, Loghin M. Treatment of spinal cord tumors. Curr Treat Options Neurol 11(4):315-24, 2009. e-Pub 2009. PMID: 19523357.
- Penas-Prado M, Loghin M. Spinal cord compression in cancer patients: Review of diagnosis and treatment. Curr Oncol Rep 10(1):78-85, 2008. PMID: 18366964.
- Loghin M, Levin VA. Headache related to brain tumors. Curr Treat Options Neurol 8(1):21-32, 2006. PMID: 16343358.
- Gilbert MR, Loghin M. The Treatment of Malignant Gliomas. Curr Treat Options Neurol 7(4):293-303, 2005. PMID: 15967092.
Abstracts
- O'Brien B, Penas-Prado M, Kamiya C, Weathers SP, Yung WK, Loghin M, Harrison RA, Bacha J, Brown D, Johnson G, Langlands J, Schwartz R, Kanekal S, Lopez L, de Groot JF.. Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the recurrent and adjuvant setting. Neuro-Oncology 21(suppl_6):vi14-vi15, 2019.
- Sinicrope KD, Barata P, Walker J, Tremont-Lukats IW, Groves M, Loghin M, Seligman C, Ferguson S, Weathers SP, Penas-Prado M, Kamiya-Matsuoka C, Harrison R, Tummala S, Trevino CR, Peinado S, Murthy RK, Seyedeh D, de Groot J, O'Brien B. Intrathecal Topotecan for Leptomeningeal Metastasis in Solid Tumors: The MD Anderson Experience. Neuro-Oncology Advances 1(suppl_1):i8, 2019.
- Kamiya Matsuoka C, Metrus N, Weathers S, Ross J, Shaw KR, Penas-prado M, Loghin ME, Alfaro-Munoz K, O'Brien BJ, Harrison R, Sadighi Z, Majd N, Yung WK, Meric-Bernstam F, Hambardzumyan D, de Groot J. Is Immuno-Oncology Therapy Effective in Hypermutator Glioblastomas with Somatic or Germline Mutations?. Annals of Oncology 30(suppl_5):v143-v158, 2019.
- Penas-Prado M, Weathers S, Zhou S, Kamiya-Matsuoka C, O'Brien B, Loghin M, Harrison R, Pei B, Ictech S, Hunter K, Yung WK, de Groot J, Shpall EJ, Heimberger A, Rezvani K. A Phase I/II Clinical Trial of Autologous CMV-Specific Cytotoxic T Cells (CMV-TC) for Glioblastoma: Dose Escalation and Correlative Results. Neuro-Oncology 20(suppl_6):vi2–vi3, 2018.
- de Groot J, Penas-Prado M, Mandel J, O'Brien B, Weathers S, Loghin M, Kamiya-Matsuoka C, Zhou S, Colen R, Hunter K, Fuller G, Huse J, Rao G, Weinberg J, Prabhu S, Ferguson S, Yuan Y, Vence L, Allison J, Sharma P, Heimberger A. Window-of-Opportunity Clinical Trial of Pembrolizumab in Recurrent Glioblastoma Patients. Neuro-Oncology 20(suppl_6):vi2, 2018.
- Metrus N, Daher A, Harrison R, Majd N, Maraka S, Nam J, Trevino C, Weathers S, O'Brien B, Kamiya-Matsuoka C, Loghin M, Alfaro K, Hunter K, Yung WK, de Groot J, Penas-Prado M. Analysis of Challenges to Accrual in Clinical Trials for Newly Diagnosed Glioblastoma. Neuro-Oncology 20(suppl_6):vi141, 2018.
- Weathers S, Kamiya-Matsuoka C, Dervin S, Yun C, Loghin M, O'Brien B, Harrison R, Yung WK, Penas-Prado M, de Groot J. Safety Run-In Results for a Phase I/II Study to Evaluate the Safety and Clinical Efficacy of Atezolizumab (Atezo; aPDL1) in Combination with Temozolomide (TMZ) and Radiation in Patients with Newly Diagnosed Glioblastoma (GBM). Neuro-Oncology 20(suppl_6):vi9–vi10, 2018.
- Maraka S, Groves MD, Mammoser AG, Melguizo-Gavilanes I, Conrad CA, Tremont I, Loghin ME, O'Brien BJ, Puduvalli VK, Sulman EP, Hess KR, Aldape KD, Gilbert MR, de GRoot JF, Yung WK, Penas-Prado M.. Phase I Factorial Study of Temozolomide Plus Memantine, Mefloquine, and Metformin as Post-Radiation Adjuvant Therapy for Newly Diagnosed Glioblastoma. Journal of Clinical Oncology 36(suppl), 2018.
- Kamiya Matsuoka C, Metrus NR, Shaw KR, Penas-Prado M, Weathers, SS, Loghin ME, Alfaro-Munoz K, Yuan Y, O'Brien BJ, Harrison, RA, Yung, WK, Meric-Bernstam F, de Groot, JF. The Natural Course of Hypermutator Gliomas. Journal of Clinical Oncology 36(suppl), 2018.
- Hasan T, Maraka S, Leeds N, Loghin ME. A Rare Case of Primary Angitis of the Central Nervous System (PACNS) Associated with Metastatic Prostate Cancer. Proceedings In: Annual American Academy of Neurology Meeting, 2017, 2017.
- Gatson N, Kamiya Matsuoka C, Rodriguez-Linares Y, Pillainayagan C, Cachia D, Chi L, Weinberg J, Tremont I, Fuller G, de Groot J, Loghin M. Gliomatosis, To Be or Not To Cerebri: An Evaluation of Host Systemic Immune Factors That Potentially Predispose to Diffuse Infiltrative Glioma Pattern. Neuro-Oncology 18(suppl_6):vi165, 2016.
- Gatson NT, Kamiya-Matsuoka C, Rodriguez-Linares Y, Pillainayagam CP, Cachia D, Daher AM, Chi TL, Weinberg JS, Tremont-Lukats IW, Fuller GN, de Groot JF, Loghin M. Gliomatosis, to be or not to cerebri?. Proceedings In: Annual American Academy of Neurology meeting, 2016, 2016.
- Raizer J, Grimm S, Penas-Prado M, Tremont I, Yung A, Avgeropoulos, Walbert T, Loghin M, Gilbert M. A Phase I-II Trial Everolimus and Sorafenib in Patients with Recurrent High-Grade Gliomas: Brain Tumor Treatment Collaborative Trial 09-01. Neuro-Oncology 17(suppl_5):v15, 2015.
- Loghin M, Melhem-Bertrandt A, Penas-Prado M, Zaidi T, Katz R. HER2 targeted therapies and leptomeningeal disease. Neuro-Oncology. In: Proceedings from the 18th Annual Meeting of the Scientific Meeting and Education Day of the Society for Neuro-Oncology, (SNO), 2013, San Francisco, CA, November 21 – 24, 2013 15(supplement 3):iii119, 2013.
- Conrad C, Yung WKA, deGroot J, Gilbert M,Loghin M, Penas-Prado M, Tremont I, Silberman S, Picker D.. Phase 1 trial of bevacizumab plus TPI 287 in adults with recurrent glioblastoma (GBM). Neuro-Oncology. In: Proceedings from the 18th Annual Meeting of the Scientific Meeting and Education Day of the Society for Neuro-Oncology, 2013, (SNO) San Francisco, CA, November 21 – 24, 2013 15(supplement 3):iii106, 2013.
- Raizer JJ, Giglio P, Hu JL, Groves MD, Merrell R, Conrad CA, Phuphanich S, Puduvalli VK, Loghin ME, Paleologos N, Yung WKA, Vaillant BD, Rudnick JD, Chamberlain MC, Vick N, Grimm SA, Tremont-Lukats I, DeGroot JF, Aldape KD, Gilbert MR. BTTC08-01: A phase II study of bevacizumab and erlotinib after radiation therapy and temozolomide in patients with newly diagnosed glioblastoma (GMB) without MGMT promoter methylation. J Clin Oncol 31, 2013 (suppl; abstr 2019). In proceedings: Annual Meeting of the American Society of Clinical Oncology (ASCO), 2013, May 31, - June 4, 2013, Chicago, IL 31, 2013.
- Case, D, Naughton MJ, Stieber VW, Bayer GK, Bilodeau PA, Moore DF, Falchuk SC, Needles BM, Piephoff J, Edenfield WJ, Giguere JK, Erickson N, Loghin ME, Shaw EG, Rapp SR. Quality of life (QOL) and cognitive status among irradiated brain tumor survivors treated with donepezil or placebo. J Clin Oncol 31, 2013 (suppl; abstr 2051). In proceedings: Annual Meeting of the American Society of Clinical Oncology (ASCO), 2013, May 31, - June 4, 2013, Chicago, IL 31, 2013.
- Penas-Prado M, Groves MD, Mammoser AG, Melguizo I, de groot, JF, Conrad CA, Tremont-Lukats I, Loghin ME, Puduvalli VK, Sulman EP, Hess, KR, Aldape KD, Gilbert MR, Yung, WKA. Phase I lead-in to a 2x2x2 factorial trial of dose-dense temozolomide, memantine, mefloquine, and metformin as postradiation adjuvant therapy of glioblastoma. J Clin Oncol 31, 2013 (suppl; abstr TPS2106 ). In proceedings: Annual Meeting of the American Society of Clinical Oncology (ASCO), 2013, May 31, - June 4, 2013, Chicago, IL 31, 2013.
- Abouharb S, Ensor J, Loghin ME, Katz R, Gonzalez-Angulo AM, Esteva FJ, Moulder SL, Valero V, Hortobagyi GN, Melhem-Bertrandt A. Leptomeningeal disease and breast cancer: Relationship of outcome and subtype. J Clin Oncol 31, 2013 (suppl; abstr 601 ). In proceedings: Annual Meeting of the American Society of Clinical Oncology (ASCO), 2013, May 31, - June 4, 2013, Chicago, IL 31, 2013.
- Zohrevand P, Loghin M. Transient Leukoencephalopathy after Intrathecal Chemotherapy Mimicking Stroke. Neurology. In Proceedings: American Academy of Neurology (AAN) meeting, New Orleans LA 4/24-4/27/2012 78, 2012.
- Hamilton JD, Wang J, Levin VA, Hou P, Loghin ME, Gilbert MR, Leeds NE, deGroot, JF, Puduvalli V, Jackson EF, Yung WKA, Kumar AJ. Normalized baseline ADC values predict problems associated with Bevacizumab treatment for glioblastoma multiforme or brain radiation induced necrosis. Neuro-Oncology. Proceedings In: 16th Annual Meeting of the Society for Neuro-Oncology, Orange County, CA, November 17 - November 20, 2011 13(Supplement 3):iii137, 2011.
- Hamilton JD, Levin VA, Hou P, Prabhu S, Loghin ME, Gilbert MR, Bassett RL, Wang J. Advanced MR imaging shows decreased vessel leakiness/edema and may predict complications in Bevacizumab therapy of brain radiation necrosis. Neuro-Oncology. Proceedings In: 16th Annual Meeting of the Society for Neuro-Oncology, Orange County, CA, November 17 - November 20, 2011 13(Supplement 3):iii142, 2011.
- Colman H, Gilbert M, Yung WKA, Aldape K, deGroot J, Conrad C, Levin V, Groves M, Loghin M, Pelloski C, Puduvalli V. A phase I study of Sorafen1B with radiation and temozolomide in newly diagnosed glioblastoma. Neuro-Oncology. Proceedings In: 16th Annual Meeting of the Society for Neuro-Oncology, Orange County, CA, November 17 - November 20, 2011 13(Supplemement 3):iii61, 2011.
- Paker AM, Chi L, Kamiya-Matsuoka C, Loghin ME. Posterior reversible encephalopathy syndrome in cancer patients. Neurology. In Proceedings: 16 Annual Scientific Meeting of the Society for Neuro-Oncology, Orange County, CA, November 17-20, 2011 78, 2011.
- Groves MD, DeGroot J, Loghin M, Conrad C, Hess K, Ictech S, Hunter K, Yung WKA. A phase I study of Temozolomide and Intrathecal Liposomal Cytarabine in patients with neuroplastic meningitis. Neuro-Oncology. Proceedings In: 16th Annual Meeting of the Society for Neuro-Oncology, Orange County, CA, November 17 - November 20, 2011 13(Supplement 3):iii43, 2011.
- Paker AM, Chi L, Ruiz MD, Loghin ME. Posterior reversible encephalopathy syndrome in patients with cancer. J Clin Oncol 29: 2011 (suppl; abstr 2561). In Proceedings: 2011 Annual American Society of Clinical Oncology (ASCO), Chicago IL, June 4-7, 2011 29, 2011.
- Puduvalli VK, Penas-Prado M, Gilbert MR, Groves MD, Hess KR, Levin VA, de Groot J, Colman H, Conrad CA, Loghin ME, Hunter K, Yung WKA. Phase I study of Vorinostat combined with Isotretinoin and Carboplatin in Adults with Recurrent Malignant Gliomas. Neuro-Oncology: In proceedings of the 2010 Annual Meeting of the Society for Neuro-Oncology (SNO), Montreal, Canada, November 18 - November 21, 2010, 2010.
- Loghin M, Groves M. Neoplastic meningitis in unknown primary neoplasms. Journal of Clinical Oncology. In: 2006 ASCO Annual Meeting Proceedings, 2006, Atlanta Georgia 24(18-S), 2006.
Book Chapters
- Loghin M, Kleiman A. Medication-Induced Neurotoxicity in Critically Ill Cancer Patients. In: Oncologic Critical Care. Springer, Cham: Switzerland, 2019.
- Majd NK, Loghin M. Leptomeningeal Disease in Solid Cancers. In: Oncologic Critical Care. Springer, Cham: Switzerland, 2019.
Grant & Contract Support
Title: | Phase III Double Blind, Placebo Controlled Study of Donepezil in Irradiated Brain Tumor Patients |
Funding Source: | NIH/NCI |
Role: | Principal Investigator-MDACC |